irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer (original) (raw)

2015, Cancer Chemotherapy and Pharmacology

17 %), diarrhea (8 %), and febrile neutropenia (8 %). The response rate and median progression-free survival were 83 % and 15 months, respectively. Conclusions XELOXIRI/bevacizumab is a feasible regimen for patients with mCRC, neutropenia was the DLT, and the RD of irinotecan is 150 mg/m 2 . The response rate observed is very promising and warrants further investigation.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact

A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer (original) (raw)

Sign up for access to the world's latest research.